Your browser doesn't support javascript.
loading
Nationwide analysis of EVAR explantation outcomes in Korea: A comprehensive dataset study.
Kim, Hyo Kee; Park, Pyoung Jae; Park, Jee Hyun; Oh, Young Ju; Jung, Cheol Woong; Jun, Heungman.
Afiliação
  • Kim HK; Department of Surgery, Korea University Guro Hospital, Seoul, Korea.
  • Park PJ; Department of Surgery, Korea University Guro Hospital, Seoul, Korea.
  • Park JH; Department of Surgery, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.
  • Oh YJ; Department of Surgery, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.
  • Jung CW; Department of Surgery, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.
  • Jun H; Department of Surgery, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.
Vascular ; : 17085381241265159, 2024 Jul 22.
Article em En | MEDLINE | ID: mdl-39037289
ABSTRACT

OBJECTIVE:

Endovascular aortic aneurysm repair (EVAR) is the primary treatment for abdominal aortic aneurysms, constituting 70%-80% of interventions. Despite initial benefits, long-term studies show increased mortality. Using nationwide data, this study assesses outcomes of EVAR, open aortic repair (OAR), and EVAR explantation (EE) in Korea, while exploring characteristics of late open conversion, including the rising EE incidence.

METHODS:

Employing the National Health Insurance Service database, covering health-related data for nearly 50 million Koreans, the study spanned from 2002 to 2020. Patients with AAA diagnoses (I71.3 or I71.4) were categorized into OAR, EVAR, and EE groups based on procedural codes. Statistical analyses, including t-tests, Fisher's exact tests, Cox proportional hazard models, and multivariate Cox regression, assessed baseline characteristics, mortality risks, and factors within the EE group.

RESULTS:

The analysis encompassed 26,195 patients, with 66.19% in the EVAR group, 31.87% in the OAR group, and 1.94% in the EE group. EVAR cases steadily increased from 2002 to 2018. Survival rates favored EVAR, followed by OAR and EE. 30-day survival was lower in EE than EVAR. Multivariate analysis for EE revealed no risk factors for 30-days survival but identified age, chronic kidney disease, high Charlson Comorbidity Index scores, and less than 6 months since EVAR as risk factors for overall mortality.

CONCLUSION:

Rising EE trends with increased EVAR adoption, particularly evident in the Korean dataset, underscore inferior outcomes. This highlights the critical need for strategic initial treatment decisions and timely interventions to enhance overall results and mitigate the unfavorable EE incidence.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Vascular Assunto da revista: ANGIOLOGIA / CARDIOLOGIA Ano de publicação: 2024 Tipo de documento: Article País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Vascular Assunto da revista: ANGIOLOGIA / CARDIOLOGIA Ano de publicação: 2024 Tipo de documento: Article País de publicação: Reino Unido